H.C. Wainwright Thinks Cormedix Inc’s Stock is Going to Recover


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cormedix Inc (NYSE MKT: CRMD), with a price target of $2. The company’s shares closed yesterday at $0.17, close to its 52-week low of $0.17.

According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.4% and a 38.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Cormedix Inc has an analyst consensus of Moderate Buy, with a price target consensus of $2.

See today’s analyst top recommended stocks >>

The company has a one-year high of $0.78 and a one-year low of $0.17. Currently, Cormedix Inc has an average volume of 1.6M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CorMedix, Inc. operates as pharmaceutical and medical device company that seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Bridgewater, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts